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Abstract
Background: Cachexia is a multi-factorial, systemic syndrome that especially affects patients with cancer of the
gastrointestinal tract, and leads to reduced treatment response, survival and quality of life. The most important
clinical feature of cachexia is the excessive wasting of skeletal muscle mass. Currently, an effective treatment is still
lacking and the search for therapeutic targets continues. Even though a substantial number of animal studies have
contributed to a better understanding of the underlying mechanisms of the loss of skeletal muscle mass, subsequent
clinical trials of potential new drugs have not yet yielded any effective treatment for cancer cachexia. Therefore, we
questioned to which degree findings from animal studies can be translated to humans in clinical practice and research.
Discussion: A substantial amount of animal studies on the molecular mechanisms of muscle wasting in cancer
cachexia has been conducted in recent years. This extensive review of the literature showed that most of their
observations could not be consistently reproduced in studies on human skeletal muscle samples. However, studies
on human material are scarce and limited in patient numbers and homogeneity. Therefore, their results have to be
interpreted critically.
Summary: More research is needed on human tissue samples to clarify the signaling pathways that lead to skeletal
muscle loss, and to confirm pre-selected drug targets from animal models in clinical trials. In addition, improved
diagnostic tools and standardized clinical criteria for cancer cachexia are needed to conduct standardized, randomized
controlled trials of potential drug candidates in the future.
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Background
Cancer cachexia is a multi-factorial, systemic syndrome
that occurs in the course of malignant diseases, espe-
cially in cancer of the gastrointestinal tract (GIT) [1, 2].
When all types of cancer are considered, cachexia affects
around 60 % of patients in the course of their disease
[3]. In gastric or pancreatic cancer even 80 % of patients
are affected [1, 2, 4, 5]. In addition, cachexia is also ob-
served in the course of benign diseases like chronic heart
failure, renal failure and chronic obstructive pulmonary
disease (COPD). The cachexia syndrome is characterized
by weight loss due to excessive wasting of skeletal muscle
and adipose tissue mass, which usually cannot be reversed
by conventional nutritional support and is frequently
accompanied by anorexia, fatigue, anemia and abnor-
mal metabolism [2, 6, 7]. In cancer patients, cachexia
can occur in every stage of disease and is associated
with a poor prognosis, reduced treatment tolerance
and a marked reduction in quality of life (QoL). The
diagnostic criteria for cancer cachexia are weight
loss >5 % or weight loss >2 % in individuals with a
body mass index (BMI) <20 kg/m2 over 6 months in
absence of simple starvation, or the presence of sar-
copenia (skeletal muscle index <7.26 kg/m2 for males
and <5.45 kg/m2 for females) with any degree of
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weight loss >2 % [8]. Furthermore, reduced food intake,
anorexia, markers of systemic inflammation like C-
reactive protein (CRP), responsiveness to chemotherapy
and the rate of cancer progression should be assessed for
the diagnosis of cancer cachexia [8]. The presence of
cachexia in cancer patients is associated with reduced
treatment response and tolerance and accounts for at least
20 % of cancer-specific mortality [2, 4, 9]. Furthermore,
cachectic patients have an elevated surgical risk. There-
fore, preservation of lean body mass can be critical for the
survival of cancer patients, but an effective treatment for
cachexia is still lacking.
Skeletal muscle wasting is the most important pheno-
typic feature of cancer cachexia and is among the principle
causes of functional impairment, respiratory complica-
tions and fatigue [10, 11]. A recent study on cachectic
patients with cancer of the GIT showed that besides the
loss of muscle mass there is a substantial loss of muscle
strength and mechanical quality [11]. In contrast to star-
vation, the non-muscle protein compartment of the body
remains relatively unaffected and the liver mass is even
increased, implying a tumor-associated metabolic con-
dition that specifically targets skeletal muscle and
subcutaneous adipose tissue [7]. Even though patho-
physiological mechanisms of the depletion of skeletal
muscle tissue during cancer cachexia have been in-
tensely studied in recent years, identification of the key
processes and therapeutic targets has been impeded by
the large number of mediators and signaling pathways
involved [12]. Furthermore, there is evidence of com-
plex tissue interactions in this systemic syndrome,
mediated through cytokines, tumor-derived factors,
hormones and neuropeptides [1, 6, 12, 13]. However, so
far the majority of studies have been conducted in ani-
mal models and studies of human muscle biopsies re-
main scarce and inconsistent [14]. The aim of this
review is to outline these discrepancies and investigate
to which degree findings from animal studies are trans-
latable into clinical practice and research.
Mediators and signaling pathways in cancer
cachexia – findings from animal models vs.
human samples
Cancer cachexia is a complex systemic syndrome that
involves a large number of systemic pro- and anti-
inflammatory mediators as well as hormones, neuro-
peptides and tumor derived factors. However, in the
following only those systemic mediators and pathways,
on which sufficient comparable studies in animals as
well as humans were available, will be first reviewed
and then discussed. Table 1 gives an overview of these
mediators and mechanisms and the findings regarding
their role in animal vs. human studies.
Cytokines
TNF-α, TRAF6
Tumor necrosis factor (TNF)-α and TNFR-1 mRNA
were shown to be elevated in several animal models of
cancer cachexia and pharmacological inhibition of TNF-
α showed a reduction in weight loss due to cancer in
rodents [15–21]. As was recently reviewed by Baracos
et al., TNF-α especially seems to play a role in the
Yoshida hepatoma and sarcoma rat model as well as the
Lewis lung carcinoma (LLC) model, but not in the C26-
Table 1 Mediators and mechanisms of skeletal muscle loss in
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or MAC16- adenocarcinoma mouse models [22]. Recently,
TNF-α receptor adaptor protein 6 (TRAF6) [23–26]
which functions as a E3 ubiquitin ligase, has also been
shown to be involved in catabolic signaling of cachexia
in LLC mice [25].
In humans, several studies also found correlations of
TNF-α serum levels with cachexia. A study on patients with
pancreatic cancer showed that serum TNF-α levels were
inversely correlated with BMI, hematocrit, hemoglobin,
serum protein and albumin levels [27] and similar observa-
tions were made in patients with prostate cancer [28, 29]
and hepatocellular carcinoma [30]. In addition, it was
shown that expression of the TNF-α gene was upregulated
in patients with pancreatic cancer and normalized after the
tumor was surgically resected [31]. Others observed signifi-
cant differences in serum TNF-α of patients and controls,
but no correlation with weight loss [32, 33]. Interestingly, a
recent study on 102 gastric cancer patients showed that
TRAF6 mRNA and protein, as well as ubiquitin mRNA
and protein, were all upregulated in skeletal muscle tissue
and correlated with disease stage and the degree of weight
loss. The positive correlation between TRAF6 and ubiquitin
expression suggests that TRAF6 may regulate ubiquitin
activity in human cancer cachexia [34].
Interleukin-6
Another pro-inflammatory mediator with a critical role
in muscle wasting during cancer cachexia is interleukin
(IL)-6 [35]. Elevated serum IL-6 levels have been ob-
served in C26 and ApcMin/+ mouse models of cancer
cachexia, and systematic administration of IL-6 to these
mice resulted in depletion of skeletal muscle and adipose
tissue and ultimately led to death. Furthermore, pharma-
ceutical inhibition of IL-6 signaling was shown to
decrease the rate of cachexia in tumor-bearing rodents
[35–39]. In skeletal muscle, the three most important
intracellular signaling pathways induced by the ligand-
receptor binding of IL-6 are the activation of JAK/STAT3,
ERK and PI3K/Akt pathways [40–42]. In vitro tests have
shown that the activation of STAT3 is both necessary and
sufficient to induce muscle wasting. ApcMin/+ mice also
showed increased activation of STAT3 in skeletal muscle
[37]. Pharmacological inhibition of STAT3 was able to
reduce muscle atrophy in mice with colon carcinoma;
however, it was not sufficient to completely attenuate
cachexia [40].
In human studies, elevated serum IL-6 levels were quite
consistently associated with weight loss and a reduced rate
of survival in cancer patients [1, 35, 40, 43–51]. Moreover,
IL-6 was shown to be significantly over-expressed in
pancreatic cancer tissue, and serum levels were signifi-
cantly elevated in cachectic compared to non-cachectic
patients with pancreatic cancer [48, 52, 53] and prostate
cancer [49].
IL-1β and INF-γ
In some animal models, IL-1 and interferon (INF)-γ
were shown to induce weight loss and anorexia, and
neutralizing IFN-γ antibodies successfully attenuated
cachexia [16]. In particular IL-1ß appears to be essen-
tially involved in the central regulation of food intake
and feeding behavior [54]. In a study of patients with
advanced upper GIT cancer or NSCLC, IL-1ß was
shown to be a better predictor of cachexia than IL-6,
which did not correlate with weight loss in this study
population [44]. In another study on GIT cancer patients,
a correlation between weight loss and serum vascular
endothelial growth factor (VEGF)-A, as well as be-
tween VEGF-A, IL-6 and IL-1 serum levels were observed
[32, 33]. However, there are also several studies that did
not find any correlation of serum cytokine levels with
weight loss or cachexia in cancer patients [55–57].
Increased proteolysis
Myostatin
Mediators of increased proteolysis in cancer cachexia
include members of the transforming growth factor
(TGF)-β family. Myostatin is a secreted protein expressed
predominantly in skeletal muscle and to a lesser extent in
cardiac muscle and adipose tissue [58–60]. It has recently
been shown that myostatin is also secreted by C26 carcin-
oma cells and other murine and human neoplasms [61].
Free myostatin binds to a high-affinity activin type-2
(ActRIIB) receptor in skeletal muscle, which induces a
range of intracellular signaling cascades leading to in-
creased proteolysis [4, 58, 59, 61, 62], as well as the inhib-
ition of anabolic pathways (IGF-1/Akt) [63–65] and
muscle regeneration [59, 61, 62, 66]. In a murine model of
cancer cachexia, inhibition of myostatin by specific anti-
bodies was able to attenuate the atrophy of skeletal muscle
and improved muscle mass and function [67, 68]. In
addition, blocking of the ActRIIB receptor attenuated the
wasting process in skeletal muscle and heart and was asso-
ciated with increased survival of tumor-bearing mice in
several models of cancer cachexia [13, 58, 69]. Further-
more, this treatment brought elevated serum levels of
myostatin back to normal and attenuated cachexia, inde-
pendently of pro-inflammatory cytokine levels [70]. Other
TGF-ß family members that act through the ActRIIB
receptor are activin A, inhibin and macrophage inhibitory
cytokine-1 (MIC-1/GDF-15) [58]. In mouse models, ani-
mals given either myostatin or activin A showed up to a
30 % decrease in muscle mass [13, 58, 71]. Furthermore,
the inhibition of activin A was able to rescue myoblasts
treated with TNF-α or IL-1 and allowed normal differenti-
ation into myotubes [72]. In addition, activin A signaling
has been linked to increased mitochondrial energy metab-
olism and oxygen consumption, supporting its role in
maintaining body weight and resting energy expenditure
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(REE) [73]. Treatment with a specific anti-activin A anti-
body was able to prevent cachexia and death in a mouse
model [13, 70]. Another member of the TGF-ß family, In-
hibin is a secreted tumor suppressor and is a competitive
antagonist of activin for the ActRIIB receptor. Inhibin de-
ficiency causes gonadal tumor growth and severe cachexia
in animals. Treatment of inhibin-deficient mice with an
ActRIIB antibody prevented cachexia, reduced tumor
growth, and prolonged survival [74, 75]. Moreover, it has
recently been shown that MIC-1 over-expressing tumor-
bearing mice showed decreased food intake and increased
loss of muscle and fat mass. The degree of serum MIC-1
elevation directly correlated with the amount of cancer-
related weight loss, which was reversed by neutralization
of MIC-1 with a specific monoclonal antibody [76].
Studies investigating the relevance of myostatin or
ActRIIB signaling in human cancer patients are scarce.
Aversa et al. observed that myostatin was significantly
increased in patients with gastric cancer who did not
lose weight, whereas Smad2 expression was unchanged.
Interestingly, in the same study, lung cancer patients
had no increase in myostatin serum levels but did have in-
creases in Smad2 expression, raising the question whether
different tumors might induce different patterns of
molecular changes within skeletal muscle tissue [77].
Proteolysis-inducing factor
A much-debated mediator of increased proteolysis and
muscle loss in cancer cachexia is the tumor derived
proteolysis-inducing factor (PIF). In experimental cancer
cachexia, PIF has been shown to induce degradation of
skeletal muscle protein via the ubiquitin proteasome sys-
tem (UPS) [78–84]. Proteolysis-inducing factor was first
isolated from the urine of tumor-bearing mice, and was
shown to induce the increased expression of proteasome
subunits and increased proteasome activity via NF-κB
[82, 85–87]. The activation of NF-κB includes the phos-
phorylation of RNA-dependent protein kinase (PKR),
which inhibits protein synthesis [78]. The relevance of this
process to cancer cachexia is demonstrated by the ability
of a PKR-inhibitor to abate skeletal muscle atrophy in a
mouse model of cachexia by attenuating UPS-dependent
proteolysis and increasing protein synthesis [88].
However, in human cancer cachexia, the existence of
a homologue to PIF is controversial [86, 89]. First, a
homologue glycoprotein was isolated from urine of
weight-losing cancer patients, and when purified and
injected into mice, it induced a 10 % loss of body
weight within 24 h [54]. Subsequently, several studies
showed an association between PIF and weight loss in
patients with cancer cachexia [90–93]. Immunohisto-
chemical staining of tumor samples from patients with
GIT cancers showed that PIF was expressed by the
tumor, which was strongly associated with weight loss
and the presence of PIF in urine samples [91]. How-
ever, the only longitudinal study on the presence of
PIF in urine of 36 GIT cancer patients showed that
over time, cancer patients positive for the PIF pattern
experienced weight loss, whereas those with a negative
test gained weight [92]. Based on the available sequence of
PIF, the factor HCAP (Human cachexia-associated pro-
tein) was identified in cell lines, in metastatic tumors and
in the urine of cancer patients with cachexia [93]. In
addition, the same research group showed that the expres-
sion of HCAP in prostate cancer cells was associated with
disease progression and the development of cachexia [93].
In contrast, other groups found that the presence of PIF
in urine did not correlate with weight loss, anorexia,
tumor response, or survival in cancer patients [89, 94].
Angiotensin II
Similar to the action of PIF, angiotensin-II (AngII) has
been shown to directly accelerate protein breakdown by
the UPS in vitro [95]. In animals, it was shown that pro-
teolytic system compounds were upregulated in skeletal
muscle by AngII, and the subsequent increase in protein
degradation was blocked by muscle-specific expression
of IGF-1 [95–97]. The action of AngII involves activa-
tion of NF-κB-dependent signaling and the formation of
reactive oxygen species (ROS) [98]. In mice with cancer
cachexia, inhibition of ROS formation by the antioxidant
α-tocopherol was able to rescue skeletal muscle mass
[80, 99]. Furthermore, in a recent study on the effect of
treatment of C26-mice with angiotensin-converting
enzyme (ACE) inhibitors, it was shown that muscle mo-
bility and strength, as well as respiratory function were
improved although body and muscle mass were not
increased [100].
However, the role of AngII in human cancer cachexia
remains to be determined. In patients with cachexia re-
lated to congestive heart failure, treatment with ACE
inhibitors caused an increase in both subcutaneous fat
and muscle mass [101]. There is also some preliminary
evidence that ACE inhibitors have the potential to ameli-
orate cancer cachexia, at least in NSCLC patients [102].
In addition, treatment with antioxidants has been shown
to be effective in increasing lean body mass, decreasing
ROS and pro-inflammatory cytokines, and improving
QoL [103].
Activation of proteolytic systems
In experimental cancer cachexia the ubitquitin-
proteasome-system (UPS) has been shown to play the
major role in the degradation of muscular proteins
[1, 15, 104, 105]. Increased mRNA levels of ubiquitin
and proteasome subunits, as well as increased proteasome
activity, have been observed in numerous animal models
of cancer cachexia [18, 38, 39, 105–110]. Treatment with
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proteasome inhibitors was successful in ameliorating
cachexia in C26-mice [111]. In animal models the regula-
tion of expression of genes for the E3-ubiquitin ligases,
muscle ring finger-1 (MuRF-1) and muscle atrophy F box
(MAfxb) has been shown to be increased in different types
of muscle atrophy, including cancer cachexia [112–120].
MuRF-1 and MAfxb expression in skeletal muscle are
regulated by transcription factors of the FoxO family
[38, 62, 112, 113, 121–124] and NF-κB [87, 125]. Fur-
thermore, the activation of the transcription factors
Smad2/3 (myostatin pathway) also increases the expres-
sion of MuRF-1 and MAfxb via FoxO [4, 58, 59, 61, 62,
104, 113, 121]. Inhibition of MAfxb in fasting mice with
muscular atrophy led to decreased expression of myosta-
tin and increased expression of the transcription factor
MyoD which is implicated in muscle regeneration [126].
Administration of IL-6 to ApcMin/+ mice induced MAfxb
expression via STAT3, whereas MuRF-1 was unaltered at
gene and protein levels [35]. These findings suggest that
MuRF-1 and MAfxb are involved in different catabolic
signaling pathways and represent a common effector.
Compared to these results from animal models, studies
of human skeletal muscle have so far produced rather
ambivalent results regarding the activation of the UPS in
cancer cachexia. Increased activity of the UPS in correl-
ation with disease severity has been demonstrated in skel-
etal muscle of patients with gastric cancer [34, 127–129],
even before the clinical onset of cachexia [128, 129]. Ac-
cordingly, it was observed that markers of systemic in-
flammation (IL-6, CRP) correlated with the increased
expression of ubiquitin in skeletal muscle biopsies from
cachetic patients with pancreatic cancer, and this increase
correlated with the degree of weight loss [130]. Muscle
proteolysis and proteasome subunit mRNA were also ele-
vated in colorectal cancer patients compared to controls,
whereas after surgical resection of the tumor, the proteoly-
sis rate was reduced to the level of healthy controls [131].
However, a study on patients with pancreatic cancer
showed that components of the UPS were only upregu-
lated in subjects with weight loss >10 % [132]. In contrast,
studies on lung cancer patients did not find any increased
expression of UPS components in skeletal muscle biopsies
[133, 134]. Other studies observed that MAfxb expression
and MuRF-1 expression were unaltered in muscle biopsies
of patients with gastric [135] and colorectal cancer [131].
Interestingly, a study on pancreatic cancer patients with
weight loss found that the expression of FoxO1 and −3
was even decreased in skeletal muscle biopsies compared
to controls [136].
Similarly, studies investigating the activation of NF-κB
in human cancer cachexia have also produced inconsistent
results. Whereas the activation of NF-κB has been shown
to be an early and sustained event in patients with gastric
cancer [137], pre-cachetic lung cancer patients did not
show any activation of muscular NF-κB-dependent in-
flammatory signaling [134]. Furthermore, two recent
studies on gene expression profiles in human cancer
cachexia showed that none of the previously described
genes, including MuRF-1, MAfxb and autophagy re-
lated genes (Atgs), were upregulated in skeletal muscle
biopsies [138, 139].
Protein-degradation via the authophagy-lysosomal sys-
tem (ALS) is getting more and more attention in the
context of cancer cachexia recently, and its regulation
has been shown to overlap with the UPS. Under physio-
logical conditions, the ALS contributes to cell survival
and adaption to stress through the controlled degradation
of dysfunctional intracellular organelles and proteins by
lysosomal proteases (cathepsins) [140]. The regulation of
autophagy induction and autophagosome formation is
dependent on gene expression of Atgs. In animal models,
Atgs (e.g. Atg7, LC3B, Bnip3, Beclin-1) have been shown to
be over-expressed during muscle atrophy [140–143] and
are partly regulated by FoxO3 [121, 143, 144] and p38-
MAPK [145, 146]. Furthermore, elevated levels of total
cathepsin activity have been observed in hepatoma-
bearing rats and treatment with a cathepsin-inhibitor was
able to attenuate muscle depletion [147, 148]. A recent
study by Penna et al. demonstrated that autophagy is
increased in C26-bearing mice as well as in Yoshida-
hepatoma rats and LLC mice [149].
However, in skeletal muscle of patients with early stages
of lung cancer, mRNA levels of the lysosomal proteases
cathepsin B and D were elevated, whereas components of
the UPS were not increased [133]. Furthermore, cathepsin
B mRNA levels correlated with fat-free mass index and
tumor stage and were higher in cancer patients who were
smokers. Since these observations were made before the
clinical onset of cachexia, it is suggested that similar to
findings from animal models, cathepsin B expression is in-
volved in the induction of cachexia in lung cancer patients
[133]. Increased levels of cathepsin D have been observed
in cancer patients with other tumor entities as well [150].
Decreased protein synthesis
In addition to the increased protein degradation, it has
been postulated that muscle atrophy in cancer cachexia is
also due to decreased protein synthesis [78, 141]. Under
physiological conditions, activation of the anabolic PI3K/
Akt/mTOR pathway results in down-regulation of MuRF-
1 and MAfxb through inhibition of FoxO [12, 119, 136]
and simultaneous stimulation of protein synthesis by acti-
vation of mammalian target of rapamycin (mTOR) and
glycogen synthase kinase 3β (GSK3β) [12, 119, 136, 151].
The PI3K/Akt/mTOR signaling cascade is activated by in-
sulin or IGF-1. Low levels of insulin or IGF-1 and elevated
levels of glucocorticoids induce the loss of muscle protein
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in diabetes, and insulin resistance is a characteristic fea-
ture of many systemic diseases with muscle wasting [152].
Activation of the protein kinase Akt was shown to be
decreased in muscle and adipose tissue of tumor-bearing,
cachectic mice [124]. In contrast, a recent study on cancer
cachexia in mice observed an increase in Akt activation,
while mTOR signaling and FoxO activity were suppressed
[38]. However, Penna et al. observed no decreased activity
of Akt in two distinct animal models of cancer cachexia
[42]. Downstream of Akt, no suppression of protein syn-
thesis was observed, with levels of activated p70S6K and
GSK3-β being normal or increased, and levels of eIF2α be-
ing decreased [42]. Other studies even found that mTOR
signaling was activated rather than suppressed during
cancer cachexia. One hypothesis is that mTOR may be ac-
tivated through the intracellular concentration of free
amino acids, which rises when protein degradation is in-
creased [153]. According to another hypothesis a certain
increase in protein synthesis is required for protein deg-
radation, and the PI3K/Akt/mTOR pathway has a dual
role. When mTOR was inhibited 30 min before the appli-
cation of PIF, protein degradation was not increased, sug-
gesting that increased proteolysis requires the activation
of mTOR [85]. In addition, Robert et al. showed that
beyond stimulating the synthesis of muscle protein,
mTOR also regulated the production of pro-cachetic
factors such as IL-6 and IL-10, and inhibition of mTOR
with rapamycin resulted in reduced IL-10 mRNA transla-
tion and ameliorated the cachectic phenotype [154].
Available data on the role and activation status of the
PI3K/Akt/mTOR pathway in cancer patients is very lim-
ited. In one study on patients with pancreatic cancer and
weight loss, decreased protein levels and activation of
Akt, mTOR, p70S6K, GSK3-ß and FoxO1 were observed
in skeletal muscle tissue compared to samples from pa-
tients with pancreatic cancer without weight loss [136].
Another study on patients with GIT-cancer and weight
loss found increased protein levels and phosphorylation
of PKR and eIF2α. Myosin levels decreased as the weight
loss increased. The linear relationship between myosin
expression and the extent of phosphorylation of eIF2α
and PKR suggests that the phosphorylation of PKR may
be an important initiator of muscle wasting in cancer
patients [155]. In addition, a study on patients with colo-
rectal cancer investigated the pattern of muscle protein
turnover before and after surgical tumor resection com-
pared to healthy controls and evaluated the anabolic
response of skeletal muscle tissue to nutrition in three
groups (control, pre-operative, post-operative). The
authors observed that myofibrillar protein synthesis in-
creased after feeding of healthy controls, whereas there
was no response in the preoperative cancer patient
group. After surgery the anabolic response to feeding
was recovered. However, in the healthy control group
and in the preoperative patient group, nutrition led to a
significant increase in p70S6K and 4E-BP1 phosphoryl-
ation, whereas in the postoperative patient group nutrition
did not lead to this effect. The phosphorylation of Akt was
unchanged in all groups. Furthermore, increased expres-
sion of proteasome subunit mRNA was observed in the
preoperative group compared to controls, but interestingly
MuRF-1 and MAfxb expression were unchanged in all
groups [131].
Inhibition of muscle regeneration
Finally, the inhibition of positive regulators of muscle
growth and regeneration factors (MRFs) also plays an
important role in cancer cachexia. The transcription fac-
tor MyoD is an essential regulator of myogenesis and
myoblast differentiation, and is crucial for regeneration
of muscle tissue from satellite cells [14, 156, 157]. MyoD
was shown to be inhibited by pro-inflammatory cyto-
kines, myostatin and PIF. The proteolysis of MyoD
during muscle atrophy was shown to be effectuated
through ubiquitination by MAfxb in vitro and in vivo, and
atrophy was attenuated by inhibition of this process [156].
Data on the impairment of MRFs in human cachexia
patients is very limited. A study on the expression of
genes involved in muscle regeneration (Pax7, MyoD,
Myf5, nMyHC, necdin) in gastric cancer patients found
that Pax7 was significantly increased in all disease stages
compared to controls, whereas MyoD and necdin were
only upregulated in early disease stages [10]. Pax7 was
also shown to be dysregulated in muscle biopsies of pa-
tients with pancreatic cancer [158]. These results suggest
that catabolic signals possibly stimulate a counteractive
regenerative response in satellite cells. However, it is
suggested that the regenerative response is dysfunctional
during cancer-induced muscle wasting. Furthermore,
these results show a possible protective role of the pro-
tein necdin, which has previously been shown to prevent
cachexia in a mouse model [10].
Discussion: signaling pathways leading to skeletal
muscle mass in cancer cachexia – can findings
from animal models be translated to humans?
General issues in cancer cachexia research and clinical
trials
The results presented in this review underline the fact
that human cancer cachexia is a heterogeneous clinical
syndrome with many variable contributing factors, all of
which cannot be reflected by an animal model. Advan-
tages of animal models clearly are the homogeneity of
study subjects and the possibility to effectively control
influencing confounders, e.g. by accurate control of diet
or exercise and the use of pair fed controls [159]. How-
ever, none of the numerous animal models is ideal to
simulate the complex biology behind human cancer
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cachexia. Too many variables are playing a role, including
tumor biology and location, host-tumor interactions, co-
morbidities, prior anti-cancer therapies and psychosocial
issues. For example, implanted tumors in syngeneic ani-
mal models are well defined and do not metastasize,
which does not accurately reflect the growth of malignant
human tumors. Furthermore, the tumors are usually im-
planted in very young animals, which undergo rapid
tumor growth up to a size of more than 10 % of the body
mass and severe wasting within days to weeks. In contrast,
growth and wasting are less aggressive in humans, where
cachexia usually occurs within months to years and tu-
mors usually don’t grow to more than 1 % of body mass
[35, 160]. Xenograft models resemble more to human
tumors, but lack of the interaction between tumor and
immune system due to the needed immunosuppression of
the animals. Genetically engineered animals develop tu-
mors spontaneously and reproduce naïve tumor-host
interactions, but the genetic alterations are expressed in
all tissue, which is also not the case in human tumorigen-
esis. Carcinogen-induced tumors in animals probably
reflect normal tumor growth and tumor-host interactions
most closely, but are tedious and costly [54]. However,
since none of the models addresses all aspects of human
cancer cachexia, use of a combination is recommended,
and careful consideration of these issues is needed before
translation to clinical research can be made [54].
Compared to the paucity of literature on experimental
cancer cachexia, studies on human samples are relatively
scarce. This might be an accessibility issue, which is why
the cooperation of researchers with surgical departments
who can easily provide intraoperative muscle biopsies
from cancer patients, should be encouraged.
Another general issue in cachexia research is the diffi-
culty of recruiting a homogeneous study cohort of cancer
patients. The clinical presentation of cachexia is becoming
more and more variable in the context of the growing pro-
portion of obese patients [12, 161]. Furthermore, skeletal
muscle mass is generally greater in men than in women,
but paradoxically loss of muscle and lean body mass is
also greater in men than in women, which is possibly due
to hormonal differences [12, 162]. There is also a great
heterogeneity in energy expenditure between patients. As
observed by Knox et al., cancer patients can be hypermet-
abolic, normal or hypometabolic [12, 160, 163]. Decreased
physical activity combined with increased REE is another
very individual and confounding element. Cancer patients
are often prone to physical inactivity due to their age and
co-morbidities. It is known that bed rest by itself causes
muscle wasting by amplifying catabolism and desensitizing
muscle cells for anabolic signals [161]. In addition, an-
orexia, reduced food intake, psychosocial issues and ag-
gressive anti-cancer therapies contribute to weight loss
and cachexia in human cancer patients [164]. Several
modern anti-cancer therapies target signaling pathways
which are important for tumorigenesis, such as Akt/
mTOR, but also regulate protein anabolism in skeletal
muscle and other tissues, so muscle wasting can probably
be partially attributed to chemotherapy [161]. Finally, it
has to be assumed that there is a genetic contribution to
cachexia as well, since even with the same tumor type and
stage, some individuals develop cachexia whereas other do
not [12]. Studies trying to identify genes for a predispos-
ition to cancer cachexia have shown that single nucleotide
polymorphisms in cytokine genes have been associated
with the prevalence of cachexia [12]. In addition, polymor-
phisms in the vitamin D receptor have been proposed as
early clinical predictors of the development of a more
aggressive form of cachexia in cancer patients [165]. Fur-
thermore, the 1082G allele in the IL-10 promoter [166]
and the C allele of the rs6136 polymorphism in the P-
selectin gene have been validated as pro-cachectic
genotypes [167]. These findings point towards the
close relationship between the innate immune system
and cancer cachexia. However, genome-wide studies
are currently lacking, and the role of genetic predis-
position has not yet been fully clarified [168].
Further problems are encountered in the design of
clinical trials for cancer cachexia therapies. How to ap-
proach such studies has been extensively discussed as a
result of the fact that many randomized controlled trials
were conducted without resulting in any approved ther-
apies [164]. A general consensus over the definition and
use of diagnostic criteria of cancer cachexia and its dif-
ferent stages has still not been reached. The use of new,
much more specific and sensitive measuring techniques
of body composition, using computed tomography (CT)
imaging and novel tracer techniques with labeled amino
acids, will allow precise quantification of muscle protein
kinetics and will facilitate the definition of more specific
endpoints and guide the evaluation of pharmaceutical
interventions [169]. A recent study comparing different
diagnostic and assessment criteria for cachexia in a
cohort of patients with advanced colorectal cancer
found that the Cancer Cachexia Study Group’s cach-
exia score was the best prognostic factor for overall
survival [170]. This score includes three diagnostic
criteria: (1) weight loss >10 %, (2) intake <1500 kcal/
d, and (3) CRP >10 mg/L. However, it does not in-
clude assessment of skeletal muscle mass, which is
increasingly seen as the primary indicator of cachexia
in the current literature. More and more studies use
CT images for the quantification and observation of
muscle wasting in cancer cachexia and have shown a
specific association between muscle loss and reduced
survival [161, 171]. To conduct comparable clinical
trials in the future, a clear definition of criteria for
cachexia is indispensable.
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Translation of findings from animal models to human
cancer cachexia therapy
Even though animal models are not sufficient to mimic
all complex aspects of cachexia in cancer patients, re-
sults from these pre-clinical studies have already led to a
substantial number of potential therapeutic targets and
approaches.
Anti-cytokine treatments
In most animal studies, serum elevation of pro-
inflammatory cytokines like TNF-α and IL-6 is associ-
ated with muscle wasting and anti-cytokine treatments
showed great promise. Unfortunately, in humans the re-
sults from investigations of the role of cytokines are com-
pletely inconsistent. Most clinical trials of inhibitors of
synthesis or activity of TNF-α have so far not proven to be
effective in preserving lean body mass in cancer patients
[9, 14, 20]. Thalidomide, an inhibitor of TNF-α and other
pro-inflammatory cytokines, was shown to be effective in
the treatment of cancer cachexia in patients with GIT can-
cers but has strong adverse side effects [161, 172–174].
Anti-TNF-α antibodies such as infliximab and etanercept
did not show any significant improvements in cachectic
patients and were not well tolerated either [175, 176].
Preclinical and clinical (phase I and II) studies per-
formed on the IL-6 antibody ALD518 in patients with
non-small cell lung cancer (NSCLC) showed that this
treatment has the potential to improve anemia, reduce
cancer-related cachexia and ameliorate fatigue, while
having minimal adverse effects [173, 177]. Other anti-IL-
6 antibodies or inhibitors (BMS 945429, selumetinib)
have also been shown to be well tolerated and improve
fatigue and loss of lean body mass [177, 178].
Currently, no anti-cytokine therapies are approved for
the treatment of cancer cachexia and further clinical tri-
als are needed to confirm their benefits. However, some
clinical studies have shown that anti-cytokine treatments
have the potential to ameliorate combination therapy
protocols [9, 12].
The discrepancies between animal and human studies
could be partly due to differences and difficulties in
measuring serum cytokine levels or simply reflect the
heterogeneity of the individual cytokine response in dif-
ferent types of cancers and patients [16]. Furthermore,
pro-inflammatory mediators (especially IL-1) not only
take effect in the inflammatory reaction but also have
central effects leading to reduced food intake and an-
orexia in a complex and individual interaction with vari-
ous hormones and neuropeptides. Another recently
identified source of these discrepancies could be that dif-
ferent C26 tumor cell lines secret different amounts of
IL-6 depending on sample storage conditions and the
number of cell passages in vitro [179]. These results
were reproduced in vivo and could implicate that
measurements of IL-6 secretion in human cancer cach-
exia samples from different laboratories might largely
vary depending on the treatment and storage conditions
of samples.
Myostastin/ActRIIB targeting treatments
Blocking of myostatin and ActRIIB signaling showed very
promising results in animal and in vitro studies. Several
clinical approaches are currently being evaluated by
pharmaceutical companies, but results are still lacking
[180]. In cachexia due to heart failure, myostatin expres-
sion has been shown to be upregulated in animals [181]
and patients [182]. In addition, increased myostatin ex-
pression has repeatedly been seen in cachectic patients
secondary to HIV/AIDS or severe COPD [60]. Further-
more, mice with a heart-specific knockout of the myosta-
tin gene appear to be resistant to skeletal muscle loss,
which indicates that targeting this pathway could be of
benefit for patients with muscle wasting in the context of
chronic heart failure and maybe also in cancer cachexia
[183, 184]. ActRIIB receptor and myostatin inhibitors are
currently being evaluated in pre-clinical trials of muscle
wasting and degenerative disorders. Among the first
agents developed for clinical settings are the monoclonal
anti-myostatin antibodies, which are currently undergoing
phase II trials in patients with NSCLC and pancreatic
cancer [161].
PIF/AngII targeting treatments
Proteolyis inducing factor (PIF) and AngII are important
cachectic factors in experimental cancer wasting as well.
In humans, however, the existence of a homologue to
the murine PIF is still debated. Wieland et al. questioned
the existence of human PIF after finding neither a cor-
relation between the presence of this protein in urine
and weight loss or survival of cancer patients, nor a spe-
cificity for malignant diseases, since they found the same
protein in patients with cachexia due to congestive heart
failure [89]. However, their study was later criticized for
its methodology, since a cross-reactive antibody was
used and western blot bands were not correctly con-
firmed [185]. In the end, results point towards a role of
PIF, especially in GIT cancer, but its relevance still re-
mains to be confirmed, and the source and mode of
action of this protein need to be determined. Concern-
ing the role of AngII in the pathophysiology of cancer
cachexia, there are currently no published studies on
human material. However, treatment with ACE inhibi-
tors was found to ameliorate cardiac cachexia, and there
are reports of unpublished results from clinical trials
started by pharmaceutical companies which point to a
possible benefit of this treatment in cancer cachexia
[102]. This hypothesis should be confirmed in random-
ized controlled trials.
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Treatments targeting increased proteolysis and decreased
protein synthesis
Components of proteolytic systems were activated in most
experimental models of cancer cachexia. However, in
cancer patients these observations were not consistently
confirmed, suggesting that different types of tumors and
individual hosts may produce different reactions of
the proteolytic systems. However, current attempts to
pharmaceutically block the enhanced activity of the
UPS by using antagonists of the inducers of prote-
asome expression, inhibitors of NF-κB signaling and
inhibitors of ubiquitin ligases or proteasome subunits
have not yet yielded any approved treatment options
[99, 186]. Inhibitors of NF-κB, such as resveratrol, thalido-
mide, ibuprofen, eicosapentaenoic acid, and beta-hydroxy-
beta-methylbutyrate, have been shown to improve skeletal
muscle mass in cachexia. In addition, proteasome inhibitors
have been shown to have positive effects in Duchenne and
Becker muscular dystrophy. However, in a study on patients
with pancreatic cancer, treatment with bortezomib showed
no beneficial effects on cachexia [187].
There is still much debate over whether the predomin-
ant component of muscle loss during cachexia is increased
proteolysis or decreased protein synthesis. However, the
anabolic Akt/mTOR pathway was identified as the most
important anabolic cascade, and cross-talk with proteo-
lytic pathways was demonstrated in animal models. How-
ever, some studies found protein synthesis to be activated
rather than suppressed. This might reflect the fact that
cachexia is a dynamic process, passing through different
stages that might be dominated either by protein break-
down or protein synthesis. For example, it is possible that
during certain stages of cachexia, protein synthesis is actu-
ally increased in skeletal muscle due to the local produc-
tion of cytokines or as a counter-regulatory phenomenon.
In this context, it becomes clear why it is hard to interpret
human studies on cancer cachexia, which usually include
heterogeneous subjects in terms of the stage of cachexia.
To overcome this problem it is essential that future stud-
ies accurately define different stages of cachexia so their
results can be stratified accordingly.
The impairment of muscle regeneration is a relatively
new aspect of muscle loss in cancer cachexia and, as
presented above, data on its role in human cancer cach-
exia remains very limited. To our knowledge no drug
targets have been preselected in this field and further
research is needed to identify and test those.
Current cancer cachexia therapy options
Considering the multidimensional background of cancer
cachexia, it is more and more the accepted view that multi-
modal therapeutic approaches, including exercise, nutrient
supplementation, appetite stimulation and pharmacological
intervention, have to be implemented and individually
tailored for patients at different stages of cachexia [5, 161].
A large-scale meta-analysis showed that nutritional inter-
ventions were successful in increasing energy intake, body
weight and some aspects of QoL [188]. The evidence for
interventions with resistance exercise training is not as ex-
tensive yet, but first results are promising [189]. Nutrient
supplementation with N3-fatty acids, e.g. eicosapentaenoic
acid or fish oil, also have shown positive effects on muscle
loss and survival; however, the evidence is not yet sufficient
for recommendation [161]. In addition, improving patients’
metabolism by insulin or metformin treatment was shown
to increase whole body fat (without counteracting muscle
loss) and survival in initial study results [161, 190]. More-
over, secondary symptoms like pain, diarrhea or stomatitis
have to be managed correctly to evaluate the efficacy of
new treatments of cancer cachexia [161, 164]. Additional
multidimensional pharmacological therapy should ideally
include drugs that target the inflammatory status, oxidative
stress, nutritional disorders, muscle catabolism, anemia,
immunosuppression, and fatigue [173]. Anti-inflammatory
drugs like COX inhibitors (indomethacin, ibuprofen) not
only reduce the inflammatory response but also have a
positive effect on REE and were shown to prolong survival
in malnourished patients with advanced cancer [191].
Finally, careful psychosocial counseling and access to self-
help groups should be provided [173]. Moreover, successful
surgical removal of the tumor and/or oncological treat-
ments should be the starting point for rehabilitation of
patients with cancer-associated muscle wasting [160].
Conclusion
In conclusion, given the heterogeneous and multi-factorial
etiology of cachexia, it is likely that this syndrome is a re-
sult of deregulation of multiple signaling pathways. It is
possible that certain pathways are involved only in a sub-
set of patients and to an individual extent, which would
determine if the patient responds to therapeutic interven-
tions on the level of intracellular signaling pathways. How-
ever, there is also a belief that treatments that preserve
muscle mass per se can improve survival and QoL of
cancer patients, regardless of the underlying molecular
mechanisms. This review shows that, even though animal
models cannot imitate all of the complex aspects of
human cancer cachexia, they provide a robust setting to
develop and test new, targeted therapies. Ultimately, fur-
ther studies on the signaling pathways that lead to skeletal
muscle loss in larger and more homogeneous cohorts of
human patients are warranted to confirm potential drug
targets identified in experimental animal models.
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